

DOCKET NO.: ISPA-3292

1631 \$
PATENT
Box 5000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

RECEIVED
OCT 23 2001

In Re Application of:

Nielsen et al.

Serial No.: 09/486,623

Group Art Unit: 1631


Filing Date: July 6, 2000

Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACIDS HAVING ANTIBACTERIAL ACTIVITY

DATE OF DEPOSIT: October 15, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.


Gwilym John Owen Attwell
REGISTRATION NO.: 45, 449

Box NON-FEE

AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action Dated September 13, 2001.
- An Amendment Supplemental to the Paper filed _____.
- Other: _____.

Applicant(s) has previously claimed small entity status under 37 CFR §1.27.

Applicant(s) by its/their undersigned attorney, claims small entity status under 37 CFR §1.27 as:

an Independent Inventor

a Small Business Concern

a Nonprofit Organization

This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.

Substitute Pages _____ of the Specification are enclosed.

An Abstract is enclosed.

_____ Sheets of Proposed Corrected Drawings are enclosed.

A Certified Copy of each of the following applications: _____ is enclosed.

An Associate Power of Attorney is enclosed.

Information Disclosure Statement.

Attached Form 1449.

A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.

Appended Material as follows: _____

Other Material as follows: Paper copy of Sequence Listing on 14 pages; diskette containing computer readable sequence listing; Statement to Support Filing and Submission in Accordance with 37 CFR §§ 1.821 through 1.825

FEE CALCULATION

No Additional Fee is Due.

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS	34	32 (20 MINIMUM)	2	\$9 EACH	\$18	\$18 EACH	\$
INDEP. CLAIMS	6	6 (3 MINIMUM)	0	\$42 EACH	\$ 0	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$18		\$

A Check is Enclosed in the Foregoing Amount Due.

Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.


The Foregoing Amount Due for Filing this Paper.

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: *October 15, 2001*



Gwilym John Owen Attwell
Registration No. 45,449

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2001 WW



#81A
Plunkett
10/27/01

RECEIVED
OCT 23 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Nielsen et al.

Serial No.: 09/486,623

Group Art Unit: 1631


Filed: July 6, 2000

Examiner: A. Marschel

For: Peptide Nucleic Acids Having Antibacterial Activity

I, Gwilym John Owen Attwell, Registration No. 45,449 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On October 15, 2001


Gwilym John Owen Attwell, Registration No 45,449

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND RESPONSE

This paper is filed in response to the Office Action dated September 13, 2001.